YOU ARE HERE: LAT HomeCollectionsAnemia


June 23, 1989
Drug Reimbursements Approved: The federal Health Care Financing Administration has agreed to reimburse kidney dialysis centers when patients use Amgen Inc.'s new Epogen drug, retroactive to June 1. Epogen is the brand name for erythropoietin, a protein developed by the Thousand Oaks biotechnology company that is used to treat chronic anemia by stimulating production of red blood cells. Amgen said the U.S. will reimburse about 80% of a patient's treatment costs, with states covering the balance.
December 8, 2007 | From Bloomberg News
Shares of Amgen Inc. fell the most in seven months Friday after the biotech company said it might revise the safety information on its biggest product, anemia drug Aranesp. Amgen fell $3.05, or 5.5%, to $52.10, the most since May 10, when a Food and Drug Administration panel suggested new restrictions in prescribing information for the anemia drug.
May 10, 2006 | From Bloomberg News
Amgen Inc. said the U.S. International Trade Commission would investigate a complaint seeking to block Roche Holding Ltd. of Switzerland from importing a rival anemia drug. Roche's experimental drug Cera, which would compete with Amgen's Aranesp and Epogen medicines, violates six U.S. patents, Thousand Oaks-based Amgen said. Amgen also is suing Roche in U.S. court to block it from introducing Cera. At a hearing in Boston today, Roche will ask a federal judge to throw out that case.
December 6, 2006 | Daniel Costello, Times Staff Writer
Amgen Inc., the Thousand Oaks-based biotech behemoth, has been a shining star in the drug industry for more than two decades. Recently, it isn't burning so brightly. This morning, Congress begins hearings about cost and safety concerns around two of the company's top-selling drugs, Epogen and Aranesp, which are used to treat nearly 2 1/2 million dialysis and cancer patients with anemia in the U.S. each year.
Amgen, a biotechnology company in Thousand Oaks, lost a round Friday in its complex legal fight with rival Genetics Institute over U.S. marketing rights for a new anti-anemia drug. Genetics Institute, based in Cambridge, Mass., and its partner, Chugai Pharmaceutical Co. of Japan, said a U.S. Appeals Court dismissed Amgen's appeal of an order by the International Trade Commission that would permit Genetics Institute and Chugai to import their version of the drug from Japan to the U.S.
January 25, 1995
A sickle cell anemia self-help organization has appealed for $1,000 to bury a 1-year-old boy who died of the disease. "Whatever it takes to get this baby out of the morgue, that is what we're going to do," said Sister Somayah, an Islamic spiritualist representing Crescent Alliance Self-Help for Sickle Cell. The coroner's office "won't release the body until all arrangements have been made," Somayah said, adding that the organization already has raised $500 for the burial. She said her group hopes a cemetery will volunteer to take the body, even if there is only a $500 down payment.
July 8, 2006 | From Reuters
An administrative law judge has allowed drug maker Roche Holding Ltd. to continue to import an experimental anemia drug at the center of a patent fight between Roche and Amgen Inc., the companies said Friday. The judge at the U.S. International Trade Commission has determined that Roche can import its experimental drug peg-EPO, also known as Cera, under an exception for clinical trials, the companies said.
November 17, 2006 | From Bloomberg News
A study linking higher doses of a Johnson & Johnson anemia drug to heart risk prompted a U.S. lawmaker to renew questions about Medicare's policy on Amgen Inc.'s identical medicine. The Medicare plan for the elderly and disabled, including people with failed kidneys, is buying excess doses of the erythropoietin anemia drug, Rep. Bill Thomas (R-Bakersfield), chairman of the House Ways and Means Committee, said in a letter Wednesday.
November 16, 2006 | Denise Gellene, Times Staff Writer
The increasingly common practice of using a synthetic form of the hormone EPO to maintain normal red blood cell levels in chronic kidney disease patients may increase cardiovascular risks, according to a study published today in the New England Journal of Medicine. The study of 1,432 patients in the U.S. found that those who had undergone the treatment had a 34% increased risk of heart attack, congestive heart failure, stroke and death, according to the study.
February 4, 1989 | From Staff and Wire Reports
Amgen Inc., a Thousand Oaks biotechnology company already embroiled in patent lawsuits over its new anti-anemia drug, has been hit with another suit from its own marketing partner, consumer products giant Johnson & Johnson. Ortho Pharmaceutical, a Johnson & Johnson unit, asked a federal court in Delaware to block Amgen's effort to get federal approval for the drug and to begin marketing it.
Los Angeles Times Articles